Replies to post #7064 on Halozyme Therapeutics Inc (HALO)

[Howeeme]

Still not sure why you are so against the financings. Last I looked they’ve made a big profit on buybacks and are paying a fixed rate of .25 percent. 77 conversion rate is $30 out of the money and so what if we have to issue 11 million shares on conversion when we paid less than 30 on average. Am I missing something?

[Howeeme]

Still not sure why you are so against the financings. Last I looked they’ve made a big profit on buybacks and are paying a fixed rate of .25 percent. 77 conversion rate is $30 out of the money and so what if we have to issue 11 million shares on conversion when we paid less than 30 on average. Am I missing something?

[maumar]

They see potential for upside from the acquisition and future Enhanze targets/new Enhanze deals but for now their 2022 EPS estimate is $2.17 (average on yahoo finance is $2.23) with a 2025 non-GAAP EPS estimate of $3.74, which translates to a 2022-2025 CAGR of 20%.

I hope Helen has good reasons to believe she can significantly expand ATRS's auto-injector platform. That would make the acquisition transformative for Halo.

[maumar]

Good news for ARGX and HALO. According to JPM, results from UCB's competing therapy for myasthenia gravis are inferior. They see Vyvgart being the leading MG product. I find it interesting that these treatments are SC and one also self-administered.

I am expecting Halo's Q1 royalties to be between $68M and $72M.


"Phase 3 RAISE and MycarinG studies in generalized myasthenia gravis (gMG) show zilucoplan and rozanolixizumab improve gMG-specific outcomes with consistent statistical significance and clinical relevance

BRUSSELS and ATLANTA, May 10, 2022 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced results from two Phase 3 studies evaluating its investigational treatments, zilucoplan, a self-administered, subcutaneous (SC) peptide inhibitor of complement component 5 (C5 inhibitor) and rozanolixizumab, an SC-infused monoclonal antibody targeting the neonatal Fc receptor (FcRn) in adults with generalized myasthenia gravis (gMG)."